Possible involvement of the endocannabinoid system in the actions of three clinically used drugs
- 1 February 2004
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 25 (2) , 59-61
- https://doi.org/10.1016/j.tips.2003.12.001
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Anandamide and vanilloid TRPV1 receptorsBritish Journal of Pharmacology, 2003
- The general anesthetic propofol increases brain N‐arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolaseBritish Journal of Pharmacology, 2003
- Amino Acid Determinants in Cyclooxygenase-2 Oxygenation of the Endocannabinoid AnandamideBiochemistry, 2003
- The therapeutic potential of cannabisThe Lancet Neurology, 2003
- Anandamide metabolism by fatty acid amide hydrolase in intact C6 glioma cells. Increased sensitivity to inhibition by ibuprofen and flurbiprofen upon reduction of extra- but not intracellular pHNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 2003
- Intrathecally applied flurbiprofen produces an endocannabinoid‐dependent antinociception in the rat formalin testEuropean Journal of Neuroscience, 2003
- Modulation of anxiety through blockade of anandamide hydrolysisNature Medicine, 2002
- Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolaseProceedings of the National Academy of Sciences, 2001
- Blockade of Effects of Smoked Marijuana by the CB1-Selective Cannabinoid Receptor Antagonist SR141716Archives of General Psychiatry, 2001
- The endocannabinoid system as a target for therapeutic drugsTrends in Pharmacological Sciences, 2000